Vertex Pharmaceuticals Incorporated and Travere Therapeutics, Inc.: A Detailed Gross Profit Analysis

Vertex vs. Travere: A Decade of Biotech Growth

__timestampTravere Therapeutics, Inc.Vertex Pharmaceuticals Incorporated
Wednesday, January 1, 201427632226519428000
Thursday, January 1, 201597707000906794000
Friday, January 1, 20161290370001491717000
Sunday, January 1, 20171513320002213533000
Monday, January 1, 20181587190002638058000
Tuesday, January 1, 20191701040003615063000
Wednesday, January 1, 20201921950005469383000
Friday, January 1, 20212207060006670200000
Saturday, January 1, 20222044260007850400000
Sunday, January 1, 20231337880008607000000
Monday, January 1, 20249489600000
Loading chart...

Unlocking the unknown

A Tale of Two Biotechs: Vertex vs. Travere

Gross Profit Growth from 2014 to 2023

In the competitive world of biotechnology, Vertex Pharmaceuticals Incorporated and Travere Therapeutics, Inc. have charted distinct paths over the past decade. From 2014 to 2023, Vertex's gross profit surged by an impressive 1,557%, reflecting its robust pipeline and strategic market positioning. In contrast, Travere Therapeutics experienced a more modest growth of 384%, highlighting its steady yet slower expansion.

Vertex's Dominance

By 2023, Vertex's gross profit reached a staggering 8.6 billion, dwarfing Travere's 134 million. This disparity underscores Vertex's dominance in the biotech sector, driven by its innovative treatments and strong market presence.

Travere's Steady Climb

Despite its smaller scale, Travere's consistent growth trajectory showcases its resilience and potential for future breakthroughs. As both companies continue to innovate, the biotech landscape remains dynamic and full of promise.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025